NCT04896528 is a Phase 2 clinical trial of Avatrombopag in Thrombocytopenia, sponsored by Peking Union Medical College Hospital.

Who is sponsoring NCT04896528?

NCT04896528 is sponsored by Peking Union Medical College Hospital.

What drugs are being tested in NCT04896528?

Interventions in NCT04896528: Avatrombopag.

What condition does NCT04896528 study?

NCT04896528 studies Thrombocytopenia, Avatrombopag.

Is NCT04896528 still recruiting?

NCT04896528 is currently status unknown. Last updated 21 May 2021.

Last reviewed 2021-05-21 · How we verify

NCT04896528

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy and Safety of Avatrombopag in Cancer Patients With Thrombocytopenia

Status unknown Phase 2 Last updated 21 May 2021

What this trial tests

Phase 2 trial testing Avatrombopag in Thrombocytopenia in 30 participants. Status unknown.

Timeline

6 June 2021

Primary endpoint
31 December 2021

31 December 2021

Quick facts

Lead sponsor	Peking Union Medical College Hospital
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	6 June 2021
Primary completion	31 December 2021
Estimated completion	31 December 2021
Sites	1 location across China

Drugs / interventions tested

Avatrombopag (AVATROMBOPAG) — full drug profile →

Conditions studied

Thrombocytopenia — all drugs for Thrombocytopenia →
Avatrombopag — all drugs for Avatrombopag →

Sponsor

Peking Union Medical College Hospital

Who can join

Adults 18 to 85, any sex, with Thrombocytopenia or Avatrombopag. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To evaluate the efficacy and safety of Avatrombopag in patients with thrombocytopenia induced by targeted therapy and immunotherapy combination treatment, and provide evidence-based medication for the clinical use of Avatrombopag in patients with PC ≤50×109/L

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Avatrombopag

Trials testing the same drug.

NCT07051915 — The Holistic Study · Phase 3 · not yet recruiting
NCT06254287 — Efficacy and Safety of Avatrombopag vs. Avatrombopag Combined With rhTPO in the Treatment of SAA · Phase 2 · unknown
NCT05772546 — Avatrombopag vs. Placebo for CIT in GI Malignancies · Phase 2 · active not recruiting
NCT05996393 — CsA+ATG+AVA vs. CsA+AVA for the Treatment of Newly-diagnosed SAA in the Elderly · Phase 4 · completed
NCT06001567 — Avatrombopag for HCC Patients With Thrombocytopenia Who Intend to Undergo TACE and/or HAIC · Phase 2 · unknown

Other recruiting trials for Thrombocytopenia

Currently open trials in the same condition.

NCT07441720 — Safety and Efficacy of Umbilical Cord Blood Therapy for Cancer Therapy-Induced Thrombocytopenia (CTIT) · Phase 2 · recruiting
NCT07442513 — Comparison of Etamsylate Versus Placebo to Prevent Bleeding in HSCT · Phase 3 · recruiting
NCT07257809 — Herombopag Treated T-DM1 Induced Platelet Reduction · Phase 2 · recruiting
NCT06676904 — Neonatal Platelet Transfusion Threshold Trial · NA · recruiting
NCT06886516 — Apixaban in Thrombocytopenia · EARLY_PHASE1 · recruiting

Other Peking Union Medical College Hospital trials

Trials by the same sponsor.

NCT07466251 — PCSK9 Inhibitor for Intracranial Atherosclerosis Related Acute Ischemic Stroke · Phase 4 · not yet recruiting
NCT06743321 — Speech-to-speech Voice-cloning Care (SVCC) to Improve ICU-acquired Anxiety for Critically Ill Patients · NA · not yet recruiting
NCT07590336 — 68Ga-NYM207 PET/CT Imaging in Hepatocellular Carcinoma · Phase 1, PHASE2 · not yet recruiting
NCT07515976 — Mapping of Genomic Structural Variations in Major Birth Defects · not yet recruiting
NCT07386756 — Early Precise Identification and Intervention Strategies for Individuals at High Risk of Prediabetes · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04896528 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Peking Union Medical College Hospital
Last refreshed: 21 May 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04896528.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing